Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,761.01 65.00 0.29%

Misonix Terminates Distribution Agreement With Aesculap



           Misonix Terminates Distribution Agreement With Aesculap

PR Newswire

FARMINGDALE, N.Y., Dec. 12, 2012

FARMINGDALE, N.Y., Dec. 12, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM:
MSON), an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery,
skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, has announced the
termination of its distribution agreement with Aesculap, Inc., for the Misonix
BoneScalpel™ Ultrasonic Bone Cutting System.

Since January 2011, Aesculap has been a non-exclusive, private label
distributor of the BoneScalpel in the United States, for clinical applications
in spine surgery and cranial surgery.  Under the non-exclusive distribution
agreement, Aesculap retains the right to sell BoneScalpel disposables to
certain, limited hospital accounts, post termination, which are covered by
binding supply agreements for varying periods of time, but not to exceed 3
years.  An additional aspect of the cancellation requires Misonix to purchase
all hardware inventory in Aesculap's possession.  This inventory will feature
prominently in the Company's plans to support its rapidly growing, proprietary
sales organization with equipment for sales, demonstration and evaluation
purposes.

Consistent with its business strategy, Misonix is committed to creating brand
equity by selling its products under its own label via its own proprietary
sales organization.  Misonix, to date, has appointed and trained upwards of 40
independent sales agencies, with more than 200 salespeople, to market its
BoneScalpel product line to neurosurgeons, spine surgeons, orthopedic surgeons
and cranio maxillo-facial surgeons, backed by its own sales & marketing
management team.

The BoneScalpel is a novel ultrasonic osteotome used for safe,
tissue-selective bone dissection that encourages en-bloc bone removal and
refined osteotomies while sparing elastic soft tissue structures.  Most users
report that the surgical field is relatively bloodless and clean.  Loss of
viable bone is minimal and controllable.  The BoneScalpel has been used
extensively for bone removal in the cervical, thoracic and lumbar spine,
including deformity surgery, as well as a variety of 'skull based' surgical
procedures. 

"We are grateful to Aesculap for their contributions, to date, to our sales
success in the USA," said Michael A. McManus, Jr., President and Chief
Executive Officer of Misonix.  "We look forward to maintaining the fine
relationship established between our companies as we move through a transition
period toward direct control of our destiny via our own direct distribution
channel.  This decision by Misonix is a continuation of our strategy to be
focused on our own unique products, to determine and manage our own strategic
direction, to completely guide new product line extensions and to ensure
complete dedication to the skills development of our BoneScalpel surgeons."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

                    Investor Relations Contacts
Misonix Contact:    Lytham Partners, LLC
Richard Zaremba     Robert Blum, Joe Dorame, Joe Diaz
631-694-9555        602-889-9700
invest@misonix.com  mson@lythampartners.com

SOURCE Misonix, Inc.

Website: http://www.misonix.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement